Clinical trials: Papilloma Virus, Human
Cervical Carcinoma, Human Papillomavirus Infection
Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)
This clinical trial evaluates the use of self-collected vaginal samples for human papillomavirus (HPV) testing in patients referred for a colposcopy and/or cervical excisional procedures to improve cervical cancer prevention.
- Trial name
- SHIP-A-S01 (NCT06498661)
- Testing
- Biospecimen Collection, Cervical Biopsy, Colposcopy
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Health Education
The Effects of Health Education About Human Papilloma Virus and Cervical Cancer Prevention on Knowledge, Attitudes, Beliefs and Behaviors
Aim: To determine the effects of health education about Human Papilloma Virus infection and cervical cancer prevention on knowledge, attitudes, beliefs and behaviors of adolescent girls and their mothers.
- Trial name
- NCT04113902
- Testing
- Health Education
- Where
- Turkey (Türkiye)
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi Gulhane Tip Fakultesi
HPV Infection
Human Papillomavirus Anal Infection
Human papillomavirus (HPV) are involved in up to 95 % of anal canal neoplastic lesions. Little is known about HPV carriage in anal canal previous to cancer occurrence in the population and pre-neoplastic lesions, and their risk…
- Trial name
- PAPILLAN (NCT02862795)
- Testing
- HPV detection in anal canal samples
- Where
- 2 sites in France
- Volunteers
- 500 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
HIV Infections, HPV - Anogenital Human Papilloma Virus Infection
Evaluation of Triage Options After HPV Testing for Cervical Cancer Screening Among HIV-infected Women
Cervical cancer is the most common cause of cancer and a leading cause of death among HIV-infected women living in resource-limited settings.
- Trial name
- AIMA-CC (NCT03789513)
- Testing
- HPV test with partial genotyping and VIA triage
- Where
- 3 sites in Burkina Faso, Cambodia and 1 more
- Volunteers
- 3,000 people
- Sponsor
- ANRS, Emerging Infectious Diseases
FGFR Gene Amplification, FGFR1 Gene Amplification
BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
This phase IIa trial studies how well the experimental drug, BGJ398 (infigratinib), works in treating patients with fibroblast growth factor receptor (FGFR) 1-3 translocated, mutated, or amplified head and neck cancer that has…
- Conditions
- FGFR Gene Amplification, FGFR1 Gene Amplification, FGFR2 Gene Amplification, FGFR2 Gene Mutation
- Trial name
- NCT02706691
- Testing
- BGJ398
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Cervical Intraepithelial Neoplasia
A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study
The purpose of this study is to evaluate the persistence of immune response in subjects who received the HPV-16/18 vaccine, seven to eight years after the last dose of primary vaccination in the HPV-058 study.
- Trial name
- NCT03355820
- Testing
- Blood sampling for antibody determination
- Where
- China
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus Infection
Immunogenicity of 9-valent HPV Vaccine
Human papillomavirus (HPV) causes the most prevalent sexually transmitted infections in the world. The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes, responsible for causing approximately…
- Trial name
- NCT05439083
- Testing
- 9-valent HPV vaccine
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Talia Sainz Costa
Normal Uterine Cervical Cytology, Uterine Cervical Dysplasia
Expression of Oncogenic Human Papillomavirus E6/E7 Protein in Tampon Self-Tests
The purpose of this study is to examine for HPV E6/E7 mRNA in tampon self-tests, and compare with the cytological and histological diagnoses.
- Conditions
- Normal Uterine Cervical Cytology, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms
- Trial name
- NCT00526370
- Where
- Denmark
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Cervical Intraepithelial Neoplasia, Cervical Cancer
Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
This is a phase II clinical study of the novel recombinant HPV 16/18 bivalent vaccine expressed in E. coli. The primary purpose of this study is to evaluate which dosage of the HPV vaccine can induce higher antibody and at the…
- Trial name
- NCT01356823
- Testing
- 30μg HPV, 60μg HPV, 90μg HPV
- Where
- China
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Cervical Cancer, Uterine Cervical Disease
A Proximity-incentive Strategy for Cervical Cancer Screening
In France, cervical cancer screening is based on a cervical smear for women aged 25 to 30 years and on High Risk- HPV (HR-HPV) testing for women aged 30 to 65 years.
- Conditions
- Cervical Cancer, Uterine Cervical Disease, Human Papilloma Virus
- Trial name
- RIDECA (NCT04716127)
- Testing
- Proximity-incentive strategy based on vaginal self-sampling for women 50 to 65 years who do not participate to cervical cancer screening
- Where
- 2 sites in France
- Volunteers
- 656 people
- Sponsor
- University Hospital, Montpellier
Cervical Cancer, Human Papilloma Virus
SMS Messaging for Invitation in the Cervical Cancer Screening Programme
A study on two different methods of invitation to participate to the cervical cancer screening programme will be conducted within a demonstration project to switch from cytology-based screening to HPV-based screening using…
- Trial name
- CERCA-SMS (NCT05362669)
- Testing
- SMS invitation, Phone call invitation
- Where
- Spain
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Institut Català d'Oncologia
Cancer of the Oropharynx
Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer
This is a Phase I study looking to evaluate the safety of dose escalated stereotactic radiotherapy (SRS) without exceeding the maximum tolerated dose in patients with high-risk human papilloma virus (HPV)- unassociated…
- Trial name
- NCT02703493
- Testing
- Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Northwell Health
Cervical Neoplasia, HPV Infections
Crossover Vaccination of Women Previously Randomized Into Protocol 04-C-N191
Background: National Cancer Institute Protocol 04-C-N191, also known as the Costa Rica Vaccine Trial, was a double-blind controlled study of the effectiveness of an experimental human papillomavirus (HPV) vaccine in preventing…
- Trial name
- NCT01086709
- Where
- Costa Rica
- Volunteers
- 5,444 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
HPV, Human Papilloma Virus
A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV
There are very little data on human papillomavirus (HPV) vaccination among the 18 million women living with HIV (WLWH) globally, who constitute a population most vulnerable to HPV and the resultant cervical cancer.
- Conditions
- HPV, Human Papilloma Virus, Human Immunodeficiency Virus
- Trial name
- NOVA-HIV (NCT05495906)
- Testing
- Nonavalent HPV vaccine
- Where
- 10 sites in Canada
- Volunteers
- 275 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
- Trial name
- NCT06319963
- Testing
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Theravectys S.A.
Human Papillomavirus Infection
Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting
This is a randomized, open label trial of HPV (human papilloma virus) vaccine, comparing an on-time administration of the third dose with delayed administration of the third dose.
- Trial name
- NCT00572832
- Testing
- Quadrivalent human papillomavirus vaccine on-time administration, Quadrivalent human papillomavirus vaccine delayed administration
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Genital Warts, Anal Cancer
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
This study is designed to evaluate the immunogenicity and tolerability of 9vHPV (9-valent HPV vaccine, V503) in 16- to 26-year old men and women.
- Conditions
- Genital Warts, Anal Cancer, Anal Intraepithelial Neoplasia
- Trial name
- NCT01651949
- Testing
- 9vHPV Vaccine
- Volunteers
- 2,520 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Cancer
Investigation of the Role of Human Papilloma Virus (HPV) in the Prognosis of Head and Neck Cancer
Human papilloma virus (HPV) is a recognised cause of some head and neck cancers. Important questions remain however, regarding the role of specific types of HPV, their effect on prognosis and different subtypes of oral…
- Trial name
- ARCAGE-NWE (NCT02049177)
- Where
- 6 sites in United Kingdom
- Volunteers
- 141 people
- Sponsor
- University of Aberdeen
Human Papilloma Virus, HPV-Related Carcinoma
A Tailored, Health Communication Intervention for HPV Vaccine Hesitant Families
The human papillomavirus (HPV) causes 90% of cervical cancers and is implicated in multiple other cancers. The HPV vaccine can prevent the vast majority of these cancers, but it is underused in adolescents, especially among those…
- Conditions
- Human Papilloma Virus, HPV-Related Carcinoma, Vaccine Refusal, Parents
- Trial name
- NCT04380623
- Testing
- Mobile Phone-Based Web-Page: HPV vaccine
- Where
- United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Meharry Medical College
HPV-Related Anal Intraepithelial Neoplasia, AIN2/3
Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
This open label study investigates a novel non-surgical approach to the treatment of HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.
- Conditions
- HPV-Related Anal Intraepithelial Neoplasia, AIN2/3, Artesunate, Alternative Treatment
- Trial name
- ART-AIN (NCT03100045)
- Testing
- Artesunate Suppositories
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Johns Hopkins University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.